The link to this web site does not imply an endorsement of, affiliation or association of any kind with this web site or the third party responsible for it the Company, its affiliates and related companies. In addition, the Company is not responsible for this web site or the information contained or collected therein. Use of this web site is entirely at your own risk and subject to its terms and conditions of use including use of Personal Information. You may not create links from other web sites to this Site without the prior permission of the Company.

A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken in order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications were considered. The guidelines were then revised after extensive feedback from participants and interested parties. A literature review is provided which identifies the quality of evidence upon which the recommendations are made. These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse and stopping treatment. Significant changes since the last guidelines were published in 2008 include the availability of new antidepressant treatment options, improved evidence supporting certain augmentation strategies (drug and non-drug), management of potential long-term side effects, updated guidance for prescribing in elderly and adolescent populations and updated guidance for optimal prescribing. Suggestions for future research priorities are also made.
This practice parameter describes the epidemiology, clinical picture, differential diagnosis, course, risk factors, and pharmacological and psychotherapy treatments of children and adolescents with major depressive or dysthymic disorders. Side effects of the antidepressants, particularly the risk of suicidal ideation and behaviors are discussed. Recommendations regarding the assessment and the acute, continuation, and maintenance treatment of these disorders are based on the existent scientific evidence as well as the current clinical practice.
张老师您好!我是刚刚读完渡过1的一名普通读者,因为我的一个朋友刚刚被诊断为精神分裂症,所以特别想了解精神类疾病和各种情况,尤其是如何治疗。读了您的书收获颇丰,只是对于朋友在医院的诊断还是有些疑虑,想请教您。 症状:注意力不集中,上课会游离,能听到别人(认识但不熟悉)说她的坏话(幻听),尤其是在安静的时候,看到别人聊天总觉得是在说自己,感觉不自在,总感觉有人在监视自己,在家里感觉不安全,在朋友家里待过半天觉得挺舒服。最近一直闹着说要转学,这样到了陌生的学校,同学就不会说她的坏话了,经常对家长提一些比较高的要求,比如买车、换大房子等等。有过一次轻生的念头,觉得每天被人监视的生活太累了,想结束痛苦的生活。(她还是个学生,一直以来较为内向,学习成绩较好,父亲长期不在家里,母亲对她学习要求严格) 通过网上查询和学习您的著作,感觉她的症状更像抑郁症,而不是精神分裂症。我也是担心医院误诊,造成耽误后期治疗的不良后果,请您答疑解惑,谢谢了。
×